Telo Genomics (TSE:TELO) has released an update.
Telo Genomics has expanded its groundbreaking minimal residual disease (MRD) clinical trial to include three additional hospitals, aiming to halve patient recruitment times and enhance the trial’s robustness. This move reflects the potential of Telo’s telomere technology in improving MRD testing, an area poised for significant growth with the MRD market expected to reach $4.1 billion by 2032. The technology promises more precise treatment response monitoring and could benefit around 170,000 North American multiple myeloma patients.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
